Earlier this year Cryo-Save announced that it has established a wholly-owned subsidiary Cryo-Save India in Bangalore. The lab, built in less than four months during the summer, has now been granted a license and the first sample sales have been completed. An important step forward for the company, not only because it is the first investment in Asia but also because the market potential is substantial there. Currently there are some 200,000 births per year just in the middle class customer segment and there is a rapidly growing awareness of the benefits of stem cells in medicine too. So the Indian market is potentially one of the largest in the world. Initially Cryo-Save will be active in five key cities.